These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 23297119

  • 21. Age-related macular degeneration: the costs to society and the patient.
    Gupta OP, Brown GC, Brown MM.
    Curr Opin Ophthalmol; 2007 May; 18(3):201-5. PubMed ID: 17435426
    [Abstract] [Full Text] [Related]

  • 22. Treatment Options for Age-Related Macular Degeneration: A Budget Impact Analysis from the Perspective of the Brazilian Public Health System.
    Elias FT, Silva EN, Belfort R, Silva MT, Atallah ÁN.
    PLoS One; 2015 May; 10(10):e0139556. PubMed ID: 26457416
    [Abstract] [Full Text] [Related]

  • 23. A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.
    Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.
    Health Technol Assess; 2008 Jun; 12(27):iii-iv, ix-124. PubMed ID: 18513468
    [Abstract] [Full Text] [Related]

  • 24. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.
    Chan CK, Gangwani RA, McGhee SM, Lian J, Wong DS.
    Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR, Moride Y, Rochon S.
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [Abstract] [Full Text] [Related]

  • 27. An epidemiological study of neovascular age-related macular degeneration in Germany.
    Krause L, Yousif T, Pohl K, CAPTAIN study group.
    Curr Med Res Opin; 2013 Oct; 29(10):1391-7. PubMed ID: 23944372
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
    Hernández-Pastor LJ, Ortega A, García-Layana A, Giráldez J.
    Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
    [Abstract] [Full Text] [Related]

  • 29. Direct medical costs of age-related macular degeneration in Italian hospital ophthalmology departments. A multicenter, prospective 1-year study.
    Garattini L, Castelnuovo E, Lanzetta P, Viscarra C, Ricci E, Parazzini F, CARMA Study Group.
    Eur J Health Econ; 2004 Feb; 5(1):22-7. PubMed ID: 15452761
    [Abstract] [Full Text] [Related]

  • 30. The burden of age-related macular degeneration: a value-based analysis.
    Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR.
    Curr Opin Ophthalmol; 2006 Jun; 17(3):257-66. PubMed ID: 16794438
    [Abstract] [Full Text] [Related]

  • 31. Age-related macular degeneration: cost-of-illness issues.
    Oneill C, Jamison J, McCulloch D, Smith D.
    Drugs Aging; 2001 Jun; 18(4):233-41. PubMed ID: 11341471
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC, Lade RJ, Adewoyin T, Chong NV.
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [Abstract] [Full Text] [Related]

  • 38. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
    Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY.
    Lancet Glob Health; 2014 Feb; 2(2):e106-16. PubMed ID: 25104651
    [Abstract] [Full Text] [Related]

  • 39. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [Abstract] [Full Text] [Related]

  • 40. Age-related macular degeneration: economic burden and value-based medicine analysis.
    Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR.
    Can J Ophthalmol; 2005 Jun; 40(3):277-87. PubMed ID: 15947797
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.